Morning Overview on MSN
The government just greenlit a daraxonrasib expanded-access program for pancreatic-cancer patients with the KRAS G12C mutation — opening the new targe…
For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, ...
Kasi: The overall response rate and the reported side effects don’t necessarily encompass the tangible impact that we're ...
"One of the most amazing things I’ve ever seen," clinician-scientist Samuel Hume wrote alongside a video clip posted on X.
Morning Overview on MSN
A single oral pill just pushed RAS-mutant lung cancer tumor response rates past 74% in first-line patients — KRAS inhibitor olomorasib cleared for pivotal read at ASCO
For patients diagnosed with advanced lung cancer driven by a specific genetic flaw called KRAS G12C, the first-line treatment ...
Two complementary studies led by researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have demonstrated a new RNA-based therapeutic strategy that ...
Johnson & Johnson has continued to build its presence in KRAS-targeting drugs for cancer with a $1 billion agreement to buy Firefly Bio and its degrader-antibody conjugate (DAC) platform. The all-cash ...
Scientists at the world's largest cancer conference have hailed the start of a new drug 'revolution'.
FGTI-2734 and sotorasib are synergistic at inhibiting the viability of sotorasib-resistant (Calu-1 and LU99) and sotorasib-sensitive (H2122 and H358) human KRAS G12C lung cancer cells. A breakthrough ...
Mutations in KRAS lead to cancer. Shown here as an example is an illustration of the KRAS G12C mutant oncogene product (center) among red and white blood cells. The G12C mutation is found in a third ...
A pancreatic cancer drug more than four decades in the making has cracked one of the most stubbornly lethal cancers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results